Disputed Paternity: The Uncertain Ancestry of Pancreatic Ductal Neoplasia

Anirban Maitra1,3 and Steven D. Leach2,3,*
1Department of Pathology
2Department of Surgery and the McKusick-Nathans Institute of Genetic Medicine
3The Sol Goldman Center for Pancreatic Cancer Research
Johns Hopkins University, Baltimore, MD 21205, USA
*Correspondence: stleach@jhmi.edu
http://dx.doi.org/10.1016/j.ccr.2012.11.015

In this issue of Cancer Cell, Kopp and colleagues report that pancreatic ductal cells are largely refractory to the induction of pancreatic neoplasia. Whereas a rare ductal subpopulation may still prove capable of neoplastic transformation, these findings refocus attention on acinar and other non-ductal cell types as initiators of this deadly neoplasm.

While malignant tumors of the pancreas can display a variety of histologic forms, the term “pancreatic cancer” is usually synonymous with a pathological diagnosis of pancreatic ductal adenocarcinoma (PDAC). As its name implies, PDAC has long been presumed to arise from pancreatic ductal epithelial cells. Along with its noninvasive precursor, pancreatic intraepithelial neoplasia (PanIN), these tumors typically display a distinctly duct-like histology, and express markers of ductal differentiation. As demonstrated for other tumor types, however, tumor histology is often misleading in determining tumor lineage, and work from Kopp et al. (2012) published in this issue of Cancer Cell reinforces the disputed paternity of pancreatic “ductal” neoplasia.

Initial clues suggesting that non-ductal cells might serve as effective cells of origin for pancreatic ductal neoplasia were provided by studies involving transgenic misexpression of individual oncogenes under the regulation of non-ductal promoter elements, in which a subset of resulting tumors displayed histologic resemblance to adult ductal epithelium (Sandgren et al., 1991). However, these similarities were ultimately proven to be only skin-deep, as additional studies of PanIN and PDAC revealed activation of transcriptional programs typically observed in embryonic pancreatic epithelium, but not in differentiated duct cells (Miyamoto et al., 2003; Park et al., 2011).

With the advent of autochthonous mouse models of pancreatic neoplasia, more recent studies have interrogated individual pancreatic cell types for the ability to generate PanIN, based upon Cre/lox-mediated activation of oncogenic Kras. Initial seminal work in this arena utilized either Pdx1Cre or Ptf1aCre alleles to activate Kras in embryonic pancreatic progenitor cells (Aguirre et al., 2003; Hingorani et al., 2003). While these studies demonstrated that embryonic activation of oncogenic Kras effectively initiated pancreatic ductal neoplasia, they provided considerably less information regarding the capacity of individual adult cell lineages to similarly serve as effective cells of origin. Based on the availability of appropriate Cre driver lines, this adult capacity was first interrogated in pancreatic acinar cells. Using either a Nestin-Cre driver to activate oncogenic Kras in exocrine progenitor cells and their acinar cell descendants (Carrière et al., 2007) or a variety of inducible Cre lines to activate Kras in adult acinar cells (De La O et al., 2008; Guerra et al., 2007; Habbe et al., 2008), these studies provided strong evidence that acinar cells could indeed serve as effective biologic parents for pancreatic ductal neoplasia. In these studies, the ability of adult acinar cells to generate PanIN was dramatically accelerated in the context of associated pancreatitis, a known risk factor for the human disease. Additional studies suggested that a permissive inflammatory microenvironment could broadly bestow PanIN-parenting capabilities, as even insulin-expressing cells
were shown to be capable of generating PanIN in the context of associated pancreatitis (Gidekel Friedlander et al., 2009).

Ironically, these studies demonstrating that pancreatic ductal neoplasia could be generated from a variety of non-ductal cell types were all completed prior to a similar definitive evaluation in actual ductal epithelial cells. However, a long-awaited detailed glimpse at the parental capacities of the ductal epithelial lineage is now available. In this new study, Kopp et al. (2012) directly compare the efficiency of PanIN formation following cell type-specific activation of oncogenic Kras in the acinar lineage using a Ptf1a<sup>CreER</sup> line and in the ductal/centroacinar lineage using a Sox9<sup>CreER</sup> line. For both lines, postnatal tamoxifen administration induced recombination in a similar proportion of target cells. Similar to prior studies using other acinar cell-specific Cre driver lines, the authors observed potent induction of PanIN lesions in Ptf1a<sup>CreER</sup> ; Kras<sup>G12D</sup> mice, an effect that was further accelerated by concomitant pancreatitis. However there was minimal-to-no PanIN induction in Sox9<sup>CreER</sup> ; Kras<sup>G12D</sup> mice, even in the presence of pancreatitis. Even when discrepant PanIN frequencies were normalized based on the greater abundance of acinar cells, the difference in PanIN-generating capabilities between the two lineages remained striking, with acinar cells at least 100-fold more effective than ductal/centroacinar cells in generating PanIN. In addition, the authors demonstrated that, within the acinar lineage, Sox9 itself was required for efficient PanIN induction, and that Sox9 overexpression enhanced both pancreatitis-associated metaplasia and Kras-induced PanIN formation within the acinar lineage.

Together, these comprehensive studies demonstrate that, while differentiated acinar cells are fully capable of generating PanIN through requisite Kras-induced Sox9 activation, ductal and centroacinar cells already expressing Sox9 are dramatically resistant to Kras-induced neoplastic transformation. In conjunction with prior studies, these findings lead to the startling recognition that the predominant Sox9-expressing ductal epithelial lineage represents the only pancreatic epithelial lineage evaluated to date that is unable to efficiently generate PanIN (Figure 1).

Before entirely disqualifying ductal and centroacinar cells from consideration as capable PanIN parents, it is necessary to consider a broad number of remaining questions and possibilities. First, it must be recognized that, while Sox9 appears to be expressed in a substantial majority of pancreatic ductal and centroacinar cells, there is considerable heterogeneity in gene expression along the ductal epithelial tree, and the distinct possibility remains that PanIN can effectively originate from a subpopulation of Sox9-negative ductal epithelial cells. In addition, the study by Kopp et al. (2012) relied on tamoxifen-induced recombination in only 12% of all Sox9-expressing cells. As acknowledged by the authors, this fraction, when further reduced by a less than uniform response to Kras even among competent cell types, means that rare Sox9-expressing cells (i.e., centroacinar cells) might not have been effectively interrogated in large numbers; perhaps these cells account for the rare PanIN lesion observed in these mice. In spite of these caveats, it remains difficult to escape the authors’ primary conclusion that the predominant ductal lineage in adult mouse pancreas remains largely refractory to Kras-mediated transformation.

While it is tempting to extend these findings to the human disease, appropriate caution is warranted. In particular, the current experimental paradigm only evaluates what can happen, i.e., the competence of individual adult murine cell types to generate PanIN in response to oncogenic Kras, as opposed to what actually does happen under conditions of spontaneous or carcinogen-induced human KRAS mutations. Certainly, murine PanIN induced by Kras activation in either embryonic pancreas or in adult acinar cells seems to bear exquisite resemblance to human PanIN, both histologically and with respect to gene expression patterns. However, prior analysis of KRAS sequences in acinar cells adjacent to human PanIN failed to identify mutant alleles (Shi et al., 2009), suggesting that acinar cell KRAS mutations are either extremely rare or rapidly induce metaplastic or neoplastic conversion to a non-acinar morphology. On the other hand, cells with features of acinar differentiation can often be identified in human PanIN, and a subset of acinar to ductal...
Chemokine to the Rescue: Interleukin-8 Mediates Resistance to PI3K-Pathway-Targeted Therapy in Breast Cancer

Robert T. Abraham1,*
1Oncology Research, Pfizer Worldwide Research and Development, 10777 Science Center Drive, CB3/1376, San Diego, CA 92121, USA
*Correspondence: robert.abraham@pfizer.com
http://dx.doi.org/10.1016/j.ccr.2012.11.012

Adaptive resistance to PI3K-mTOR inhibitors potentially limits the clinical antitumor activities of these agents. In this issue of Cancer Cell, Britschgi and coworkers show that certain tumors acquire resistance to PI3K-mTOR inhibitors through activation of a JAK2-dependent pathway, leading to interleukin-8 secretion.

More than 25 years have passed since the discovery of phosphoinositide 3-kinase (PI3K) as an oncprotein-associated enzymatic activity. The term “PI3K” in this context designates the Class I subset of phosphoinositide kinases (comprising the α, β, γ, and δ isoforms), which convert phosphatidylinositol-4,5-bisphosphate to the bioactive second messenger phosphatidylinositol-3,4,5-trisphosphate (Vanhaesebroeck et al., 2012). These PI3Ks are activated, directly or indirectly, by a variety of cell surface receptors that include receptor tyrosine kinases (RTKs) and G protein-coupled receptors. Several cardiac alterations elicited by PI3K activation include changes in cell proliferation, survival, migration, and metabolism, and are highly aligned with the “hallmarks of cancer” discussed by Hanahan and Weinberg (2011). Indeed, inappropriate activation of the PI3K pathway has been observed in a remarkably broad array of human cancers. Nested within this pro-oncogenic signaling network are two pivotal protein serine-threonine kinases, AKT (also termed protein kinase B) and mTOR, both of which represent druggable targets, like PI3K itself. This combination of biological relevance and pharmacological tractability rendered the PI3K pathway an irresistible target for cancer drug discovery. The ensuing efforts in...